New Jersey-based drugmaker Celgene and certain former executives were hit with a securities lawsuit Tuesday in New Jersey District Court. The 144-page complaint contends that the defendants misled investors about multiple problems with sales of the psoriasis drug Otezla, as well as the viability of the multiple sclerosis drug Ozanimod. The case was brought by Rolnick Kramer Sadighi on behalf of Blackstone Alternative Investment Fund and other plaintiffs, Counsel have not yet appeared for the defendants. The case is 2:22-cv-02404, Healthcor Offshore Master Fund, L.P. et al v. Celgene Corporation et al.
This suit was surfaced by Law.com Radar, a source for high-speed legal news and litigation updates personalized to your practice. Law.com Radar publishes daily updates on just-filed federal cases like this one. Click here to get started and be first to know about new suits in your region, practice area or client sector.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
